全文获取类型
收费全文 | 2425篇 |
免费 | 245篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 99篇 |
妇产科学 | 19篇 |
基础医学 | 272篇 |
口腔科学 | 71篇 |
临床医学 | 258篇 |
内科学 | 497篇 |
皮肤病学 | 87篇 |
神经病学 | 215篇 |
特种医学 | 50篇 |
外科学 | 486篇 |
综合类 | 56篇 |
一般理论 | 5篇 |
预防医学 | 145篇 |
眼科学 | 119篇 |
药学 | 132篇 |
中国医学 | 4篇 |
肿瘤学 | 153篇 |
出版年
2023年 | 13篇 |
2022年 | 21篇 |
2021年 | 62篇 |
2020年 | 42篇 |
2019年 | 70篇 |
2018年 | 59篇 |
2017年 | 49篇 |
2016年 | 46篇 |
2015年 | 61篇 |
2014年 | 79篇 |
2013年 | 88篇 |
2012年 | 127篇 |
2011年 | 141篇 |
2010年 | 92篇 |
2009年 | 68篇 |
2008年 | 132篇 |
2007年 | 161篇 |
2006年 | 142篇 |
2005年 | 162篇 |
2004年 | 146篇 |
2003年 | 124篇 |
2002年 | 121篇 |
2001年 | 24篇 |
2000年 | 19篇 |
1999年 | 24篇 |
1998年 | 28篇 |
1997年 | 24篇 |
1996年 | 21篇 |
1995年 | 19篇 |
1994年 | 16篇 |
1992年 | 22篇 |
1990年 | 17篇 |
1989年 | 24篇 |
1988年 | 17篇 |
1987年 | 16篇 |
1986年 | 29篇 |
1984年 | 16篇 |
1983年 | 29篇 |
1982年 | 17篇 |
1981年 | 22篇 |
1980年 | 12篇 |
1977年 | 14篇 |
1975年 | 16篇 |
1974年 | 16篇 |
1973年 | 11篇 |
1965年 | 11篇 |
1963年 | 12篇 |
1962年 | 12篇 |
1961年 | 14篇 |
1960年 | 21篇 |
排序方式: 共有2682条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Donald B. Penzien PhD ; Frank Andrasik PhD ; Brian M. Freidenberg PhD ; Timothy T. Houle PhD ; Alvin E. Lake III PhD; Gay L. Lipchik PhD ; Kenneth A. Holroyd PhD ; Richard B. Lipton MD ; Douglas C. McCrory MD ; Justin M. Nash PhD ; Robert A. Nicholson PhD ; Scott W. Powers PhD ABPP ; Jeanetta C. Rains PhD ; David A. Wittrock PhD 《Headache》2005,45(S2):S110-S132
Guidelines for design of clinical trials evaluating behavioral headache treatments were developed to facilitate production of quality research evaluating behavioral therapies for management of primary headache disorders. These guidelines were produced by a Workgroup of headache researchers under auspices of the American Headache Society. The guidelines are complementary to and modeled after guidelines for pharmacological trials published by the International Headache Society, but they address methodologic considerations unique to behavioral and other nonpharmacological treatments. Explicit guidelines for evaluating behavioral headache therapies are needed as the optimal methodology for behavioral (and other nonpharmacologic) trials necessarily differs from the preferred methodology for drug trials. In addition, trials comparing and integrating drug and behavioral therapies present methodological challenges not addressed by guidelines for pharmacologic research. These guidelines address patient selection, trial design for behavioral treatments and for comparisons across multiple treatment modalities (eg, behavioral vs pharmacologic), evaluation of results, and research ethics. Although developed specifically for behavioral therapies, the guidelines may apply to the design of clinical trials evaluating many forms of nonpharmacologic therapies for headache. 相似文献
5.
Amy C Y Lo Alvin K H Cheung Victor K L Hung Chung-Man Yeung Qing-Yu He Jen-Fu Chiu Stephen S M Chung Sookja K Chung 《Journal of cerebral blood flow and metabolism》2007,27(8):1496-1509
Previously, we reported that transgenic mice overexpressing endothelin-1 in astrocytes showed more severe neurological deficits and increased infarct after transient focal ischemia. In those studies, we also observed increased level of aldose reductase (AR), the first and rate-limiting enzyme of the polyol pathway, which has been implicated in osmotic and oxidative stress. To further understand the involvement of the polyol pathway, the mice with deletion of enzymes in the polyol pathway, AR, and sorbitol dehydrogenase (SD), which is the second enzyme in this pathway, were challenged with similar cerebral ischemic injury. Deletion of AR-protected animals from severe neurological deficits and large infarct, whereas similar protection was not observed in mice with SD deficiency. Most interestingly, AR(-/-) brains showed lowered expression of transferrin and transferrin receptor with less iron deposition and nitrotyrosine accumulation. The protection against oxidative stress in AR(-/-) brain was also associated with less poly(adenosine diphosphate-ribose) polymerase (PARP) and caspase-3 activation. Pharmacological inhibition of AR by Fidarestat also protected animals against cerebral ischemic injury. These findings are the first to show that AR contributes to iron- and transferrin-related oxidative stress associated with cerebral ischemic injury, suggesting that inhibition of AR but not SD may have therapeutic potential against cerebral ischemic injury. 相似文献
6.
OBJECTIVES: To review the role of conventional and new treatment modalities in the management of neovascular age-related macular degeneration. DATA SOURCES AND EXTRACTION: Literature search of Medline till March 2007, using the key words/terms 'treatment' and 'age-related macular degeneration' to retrieve relevant original papers and review articles. DATA SYNTHESIS: Age-related macular degeneration is the leading cause of irreversible visual loss in the elderly in developed countries. Neovascular age-related macular degeneration has a relentless course and the consequent visual loss is debilitating. Successful treatment has always been a challenge due to poor understanding of its pathogenesis. Laser photocoagulation and photodynamic therapy with verteporfin are the standard conventional treatments. However, these approaches do not prevent disease recurrence and repeated treatments are required. Recent advances in understanding the molecular pathway for the angiogenesis of neovascular age-related macular degeneration enables exploration of new treatment approaches. Antiangiogenic therapy with anti-vascular endothelial growth factor agents, such as pegaptanib and ranibizumab, have recently been approved for clinical practice. Other antiangiogenic agents include bevacizumab, triamcinolone, and anecortave are also being evaluated in clinical trials. Additional treatment modalities include transpupillary thermotherapy and surgical intervention. CONCLUSIONS: Regarding patients with neovascular age-related macular degeneration, increased understanding in its pathogenesis coupled with rapid development in instrumental technology and new/emerging medications greatly expands available treatment options. Despite these various therapeutic options, current treatment is mainly directed at achieving visual stabilisation. Restoration of vision with newer agents is limited and not possible in every patient. Thus, early recognition and treatment to arrest the progression of neovascular age-related macular degeneration is the preferred means of attaining the best visual outcome. 相似文献
7.
R C Peffer D J Abraham M A Zemaitis L K Wong J D Alvin 《Drug metabolism and disposition》1987,15(3):305-311
The metabolism of the antisickling agent 3,4-dichlorobenzyloxyacetic acid (3,4-DCBAA) was examined after ip administration to rats. Within 5 days after administration of radiolabeled 3,4-DCBAA, 77.4 +/- 4.6% of the dose was recovered in the urine and only 3.2 +/- 0.5% was recovered in the feces. Metabolites in the urine were isolated and characterized by HPLC, electron impact MS, and LC/MS, and their identities were confirmed by comparing their spectra with those of synthetic standards. Quantitation of these urinary metabolites revealed that the majority of the radioactive dose was excreted as a taurine conjugate (60.1 +/- 4.4%), while lesser amounts were excreted as 3,4-dichlorohippurate, unchanged 3,4-DCBAA, the glycine conjugate of 3,4-DCBAA, and a polar unknown which is believed to be glycolic acid. A pathway involving an initial O-dealkylation at the benzyl carbon of 3,4-DCBAA and proceeding through the glycine conjugation of 3,4-dichlorobenzoic acid has been proposed to explain the formation of 3,4-dichlorohippurate and the polar unknown. The extensive conjugation of 3,4-DCBAA with taurine is an unprecedented observation in rats, which usually utilize glycine for amino acid conjugation reactions. Further studies with 3,4-DCBAA may provide insight into the enzymatic mechanisms of taurine conjugation, which are not well defined at this time. 相似文献
8.
9.
10.